EMEA-001501-PIP08-20
Key facts
| Invented name |
Dupixent
|
| Active substance |
dupilumab
|
| Therapeutic area |
Oto-rhino-laryngology
|
| Decision number |
P/0121/2021
|
| PIP number |
EMEA-001501-PIP08-20
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of chronic rhinosinusitis without nasal polyposis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Sanofi Winthrop Industrie
Email: contact-us@sanofi.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|